{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-016792","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.972305+00:00","generated_at":"2026-05-16T02:17:13.113868+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics licenses SYN-020 to Rasayana for $300K upfront, up to $38M milestones","bullets":["Upfront payment of $300,000 received; eligible for $16M development/regulatory and $22M sales milestones.","Tiered single-digit royalties on net sales of SYN-020; Rasayana assumes all development and commercialization costs.","SYN-020 is an oral IAP enzyme with Phase 1 safety data; Rasayana plans Phase 2 testing.","Theriva to focus on lead pancreatic cancer program VCN-01 following out-license."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-016792","json":"https://secwatch.observer/filing/0001104659-26-016792.json","markdown":"https://secwatch.observer/filing/0001104659-26-016792.md","text":"https://secwatch.observer/filing/0001104659-26-016792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/tm266493d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:17:13.113868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24ac7b0ff5b87062ba719e7090696a20cbd26803","claim":"Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).","evidence_excerpt":"On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Rasayana Therapeutics, Inc."},{"label":"Value","value":"$300,000"},{"label":"Effective","value":"2026-02-18"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}